IL12B抗体—艾普蒂

+ +

•  

   

     Flow cytometric analysis of Raji cells using FCER2 mouse mAb (green) and negative control (purple).    

  
  

The IL12B antibody targets interleukin-12 subunit beta (IL12B), a key component of the pro-inflammatory cytokines IL-12 and IL-23. IL12B, also known as p40. pairs with IL12A (p35) to form IL-12. and with IL23A (p19) to form IL-23. Both cytokines play critical roles in immune responses: IL-12 drives T-helper 1 (Th1) cell differentiation and interferon-γ production, while IL-23 promotes Th17-mediated inflammation. Dysregulation of these pathways is implicated in autoimmune diseases like psoriasis, psoriatic arthritis, and inflammatory bowel disease (IBD).

IL12B antibodies, such as ustekinumab, selectively block the p40 subunit, inhibiting IL-12 and IL-23 signaling. By neutralizing these cytokines, the antibodies reduce pathogenic Th1/Th17 responses and downstream pro-inflammatory mediators (e.g., TNF-α, IL-17). Ustekinumab, a human monoclonal IgG1 antibody, was the first IL12B-targeting biologic approved for moderate-to-severe plaque psoriasis (2009) and later for Crohn's disease and psoriatic arthritis.

Clinical trials demonstrate significant efficacy in reducing disease activity and improving patient outcomes. However, long-term safety monitoring remains essential due to potential infection risks linked to broad immune modulation. Ongoing research explores IL12B antibodies in other Th1/Th17-driven conditions, including multiple sclerosis and sarcoidosis, while newer biologics aim to refine targeting (e.g., dual IL-12/IL-23 inhibition vs. selective IL-23 blockade). This therapeutic approach highlights the central role of IL12B in chronic inflammation and its value as a drug target.